1-5 of 5
David F. McDermott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma

Available to Purchase
Renee Maria Saliby, Talal El Zarif, Ziad Bakouny, Valisha Shah, Wanling Xie, Ronan Flippot, Thomas Denize, M. Harry Kane, Katrine N. Madsen, Miriam Ficial, Laure Hirsch, Xiao X. Wei, John A. Steinharter, Lauren C. Harshman, Ulka N. Vaishampayan, Mariano Severgnini, David F. McDermott, Gwo-Shu Mary Lee, Wenxin Xu, Eliezer M. Van Allen, Bradley A. McGregor, Sabina Signoretti, Toni K. Choueiri, Rana R. McKay, David A. Braun
Journal: Cancer Immunology Research
Cancer Immunol Res (2023) 11 (8): 1114–1124.
https://doi.org/10.1158/2326-6066.CIR-22-0996
Published: 03 August 2023
View articletitled, Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Open the PDF for Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

Free
Rupal S. Bhatt, Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman, Chun-Hau Chen, Opeyemi A. Jegede, Paul J. Catalano, Jean-Christophe Pignon, Maura Sticco-Ivins, Baogong Zhu, Ping Hua, Jo Soden, Jie Zhu, David F. McDermott, Antonio R. Arulanandam, Sabina Signoretti, Gordon J. Freeman
Journal: Cancer Immunology Research
Cancer Immunol Res (2021) 9 (2): 156–169.
https://doi.org/10.1158/2326-6066.CIR-20-0315
Published: 03 February 2021
View articletitled, KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Open the PDF for KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1 in another window
Includes: Supplementary data
Journal Articles

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events

Free
Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandao, Craig K. Norton, John A. Steinharter, Katherine M. Krajewski, Xin Gao, Fabio A. Schutz, Bradley McGregor, Dominick Bossé, Aly-Khan A. Lalani, Guillermo De Velasco, M. Dror Michaelson, David F. McDermott, Toni K. Choueiri
Journal: Cancer Immunology Research
Cancer Immunol Res (2018) 6 (4): 402–408.
https://doi.org/10.1158/2326-6066.CIR-17-0220
Published: 01 April 2018
View articletitled, Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Open the PDF for Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events in another window
Journal Articles

Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2

Free
Michael K.K. Wong, Michael A. Morse, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Hong Hua, Sandra Aung
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): B140.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B140
Published: 03 January 2016
View articletitled, Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2
Journal Articles

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Free
Marcella Callea, Laurence Albiges, Mamta Gupta, Su-Chun Cheng, Elizabeth M. Genega, André P. Fay, Jiaxi Song, Ingrid Carvo, Rupal S. Bhatt, Michael B. Atkins, F. Stephen Hodi, Toni K. Choueiri, David F. McDermott, Gordon J. Freeman, Sabina Signoretti
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10): 1158–1164.
https://doi.org/10.1158/2326-6066.CIR-15-0043
Published: 04 October 2015
View articletitled, Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Open the PDF for Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma in another window
Includes: Supplementary data